本报讯（记者 左妍）日前，上海市质子重离子医院二期重离子系统设备、质子系统设备项目可行性研 究报告正式获批复，医院二期项目再迎新突破。 为进一步加大优质粒子诊疗服务供给，提升服务能级，让尖端放疗技术惠及更多肿瘤患者，保持上海在 粒子放疗领域的先发优势和领先地位，上海市质子重离子医院二期项目将新增配置1套重离子治疗系统 设备和1套质子治疗系统设备。其中，重离子系统设备设4个治疗室（含3个临床用治疗室和1个研究用治 疗室），质子系统设备设2个旋转机架治疗室，两套系统设备包括加速器及束流输运系统、治疗系统和 治疗辅助系统等。项目建设资金由上海市级建设财力安排。 此前，上海市质子重离子医院二期工程项目已于2025年9月正式开工，规划新建一栋集医疗、科研、教 学等功能于一体的医疗综合楼及相关配套设施，新建总建筑面积近7万平方米。现场已进入打桩施工阶 段，预计2028年年底基建竣工。二期项目投用后，医院有望成为全球规模最大的肿瘤粒子放疗中心。 上海市质子重离子医院目前可收治50余种肿瘤疾病，自2015年5月运营以来，已累计粒子治疗出院患者 近8900例，年平均增幅16.2%，76%的患者采用单纯重离子或重离子联合质子治疗 ...

Summary of Key Points Core Viewpoint - In September 2025, the global healthcare sector experienced a significant increase in financing activities, with a total of 175 financing events and a disclosed total amount of approximately $10.188 billion (about 727.16 billion RMB), marking a substantial growth compared to previous months [7][8][9]. Financing Overview - A total of 175 financing events occurred in September 2025, with 68 events in the domestic market amounting to approximately $9.56 million and 107 events overseas totaling about $92.32 million, indicating a strong overseas market presence [7][8]. - The financing scale saw a month-on-month increase of approximately 183.09%, with the number of events rising by about 15.13% compared to August [9][10]. Sector Performance - The biopharmaceutical sector had the highest number of financing events, totaling 73 (41.71% of the total), while the digital health sector attracted the highest financing amount of $5.773 billion (56.67% of the total) [15][16]. - Notable large financing events included Shields Health Solutions, which secured $3.5 billion, and Kriya Therapeutics, which raised $320 million for chronic disease gene therapy [10][15]. Financing Distribution - The financing rounds were predominantly in the A round (31%), followed by B round (18%), and undisclosed rounds (17%), indicating a strong activity in early and growth-stage financing [14][15]. - The funds raised were primarily allocated for clinical trial advancements, product development and commercialization, global market expansion, and technology platform upgrades [15]. Major Financing Events - Significant financing events included: - Shields Health Solutions raised $3.5 billion to enhance its pharmacy services [33]. - Kriya Therapeutics completed a $320 million D round for gene therapy development [25]. - Strive Health raised $550 million for remote kidney care services [27]. - Oura Health secured $875 million for global expansion of its smart ring technology [21]. - Galvanize Therapeutics raised $100 million for its medical device technology [32]